Prognostic value of tumor microenvironment based on PD-L1 expression and CD8+TILs density in locally advanced NSCLC treated with concurrent chemoradiotherapy

被引：0
|
作者：
Kaesmann, Lukas [2 ]
Gennen, Kathrin [1 ]
Taugner, Julian [1 ]
Eze, Chukwuka [1 ]
Karin, Monika [1 ]
Roengvoraphoj, Olarn [1 ]
Neumann, Jens [1 ]
Tufman, Amanda [3 ]
Orth, Michael [1 ]
Reu, Simone [1 ]
Belka, Claus [1 ]
机构：
[1] Univ Hosp, Munich, Germany
[2] Univ Munich, Munich, Germany
[3] Thorac Oncol Ctr Munich, Munich, Germany
来源：
JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P134
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Deciphering The Tumor Immune Microenvironment Based on CD8+TiL Density and PD-L1 Expression in Locally Advanced NSCLC Treated with Concurrent Chemoradiotherapy
    Kaesmann, Lukas
    Gennen, Kathrin
    Taugner, Julian
    Eze, Chukwuka
    Roengvoraphoj, Olam
    Neumann, Jens
    Tufman, Amanda
    Orth, Michael
    Reu, Simone
    Belka, Claus
    Manapov, Farkhad
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 119 - 119
  • [2] Prognostic value of PD-L1 expression in locally advanced NSCLC treated with chemoradiotherapy
    Gennen, K.
    Kaesmann, L.
    Eze, C.
    Dantes, M.
    Roengvoraphoj, O.
    Taugner, J.
    Neumann, J.
    Mille, E.
    Tufman, A.
    Huber, R. M.
    Orth, M.
    Reu, S.
    Niyazi, M.
    Belka, C.
    Manapov, F.
    RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S403 - S403
  • [3] Deciphering the tumor microenviroment based on PD-L1 expression and CD8+TILs density in LA-NSCLC
    Kaesmann, L.
    Gennen, K.
    Taugner, J.
    Eze, C.
    Karin, M.
    Roengvoraphoj, O.
    Neumann, J.
    Tufman, A.
    Orth, M.
    Reu, S.
    Belka, C.
    Manapov, F.
    RADIOTHERAPY AND ONCOLOGY, 2020, 152 : S533 - S533
  • [4] Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
    Kathrin Gennen
    Lukas Käsmann
    Julian Taugner
    Chukwuka Eze
    Monika Karin
    Olarn Roengvoraphoj
    Jens Neumann
    Amanda Tufman
    Michael Orth
    Simone Reu
    Claus Belka
    Farkhad Manapov
    Radiation Oncology, 15
  • [5] Prognostic value of PD-L1 expression on tumor cells combined with CD8+TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
    Gennen, Kathrin
    Kaesmann, Lukas
    Taugner, Julian
    Eze, Chukwuka
    Karin, Monika
    Roengvoraphoj, Olarn
    Neumann, Jens
    Tufman, Amanda
    Orth, Michael
    Reu, Simone
    Belka, Claus
    Manapov, Farkhad
    RADIATION ONCOLOGY, 2020, 15 (01)
  • [6] PD-L1 expression as prognostic factor for survival after chemoradiotherapy of locally advanced NSCLC
    Vrankar, M.
    Kern, I.
    Stanic, K.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (04) : S107 - S107
  • [7] Radiomic CT Features for Evaluation of PD-L1, CD8+TILs and Foxp3+TILs Expression in Stage I NSCLC
    Wen, Q.
    Linlin, W.
    Jian, Z.
    Tong, B.
    Yong, Y.
    Xindong, S.
    Jinming, Y.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S1155 - S1155
  • [8] Prognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy
    Gennen, K.
    Kaesmann, L.
    Eze, C.
    Dantes, M.
    Roengvoraphoj, O.
    Taugner, J.
    Neumann, J.
    Tufman, A.
    Orth, M.
    Reu, S.
    Belka, C.
    Manapov, F.
    ANNALS OF ONCOLOGY, 2019, 30 : 11 - 11
  • [9] Deciphering Microenvironment of NSCLC based on CD8+TIL Density and PD-1/PD-L1 Expression
    Lin, Ziying
    Gu, Jincui
    Cui, Xiaoxian
    Huang, Lixia
    Li, Shaoli
    Feng, Jinlun
    Liu, Baomo
    Zhou, Yanbin
    JOURNAL OF CANCER, 2019, 10 (01): : 211 - 222
  • [10] CT Radiomics Features for Evaluation of PD-L1, CD8+TILs and Foxp3+TILs Expression Status in Patients with Stage I NSCLC
    Wen, Q.
    Meng, X.
    Zhu, J.
    Yin, Y.
    Yu, J.
    MEDICAL PHYSICS, 2017, 44 (06)
12345